Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 17/20 | 0.61 |
| ▸ | SRC | P12931 | 11/20 | 0.60 |
| ▸ | SYK | P43405 | 11/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6300971 | 0.91 | GSK3A (0.71) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6300001 | 0.90 | GSK3A (0.56) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6546544 | 0.90 | MAPK14 (0.64) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6546434 | 0.89 | GSK3A (0.64) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6546566 | 0.89 | GSK3A (0.58) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6547071 | 0.88 | GSK3A (0.69) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6298537 | 0.88 | MAPK14 (0.62) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6643812 | 0.88 | GSK3A (0.57) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6306063 | 0.88 | GSK3A (0.64) | GSK3ASRCSYKMAPK14CYP3A4 | |
| SCHEMBL6298778 | 0.88 | GSK3A (0.52) | GSK3ASRCSYKMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852717-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | claimed |
| EP-1392661-A1 | DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | US | claimed |
| WO-2002092576-A1 | DIARYLUREA DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-6852717-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008868-A1 | Compounds useful as anti-inflammatory agents | TNF, MPO, PTGES | GSK3A 3334/4885SRC 3231/4885SYK 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.